Aquestive Therapeutics, Inc. Operating Lease, Liability, Noncurrent
Aquestive Therapeutics, Inc. (AQST) had Operating Lease, Liability, Noncurrent of $7.53 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability, Noncurrent $7.53M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $4.16M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $4.34M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $4.51M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $7.53M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $4.16M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $4.34M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $4.51M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $4.67M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $4.82M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $4.97M 10-K · filed 2026-03-04 |
| 2024-09-30 | $5.11M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $5.24M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $5.28M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $5.40M 10-K · filed 2025-03-05 |
| 2023-09-30 | $5.51M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $5.61M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $5.71M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $5.08M 10-K · filed 2024-03-05 |
| 2022-09-30 | $1.34M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $1.50M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $1.71M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $1.95M 10-K · filed 2023-03-31 |
| 2021-09-30 | $2.19M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $2.42M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $2.63M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $2.85M 10-K · filed 2022-03-08 |
| 2020-09-30 | $3.05M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $3.24M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $3.42M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |